Biltmore Family Office LLC Sells 26 Shares of Eli Lilly and Company (NYSE:LLY)

Biltmore Family Office LLC trimmed its position in Eli Lilly and Company (NYSE:LLY) by 0.8% during the 4th quarter, HoldingsChannel reports. The firm owned 3,267 shares of the company’s stock after selling 26 shares during the quarter. Biltmore Family Office LLC’s holdings in Eli Lilly and Company were worth $2,522,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in LLY. Disciplined Investors L.L.C. bought a new position in Eli Lilly and Company during the fourth quarter valued at $207,000. OneAscent Financial Services LLC grew its position in Eli Lilly and Company by 179.6% in the fourth quarter. OneAscent Financial Services LLC now owns 4,798 shares of the company’s stock worth $3,704,000 after acquiring an additional 3,082 shares in the last quarter. Private Portfolio Partners LLC increased its stake in Eli Lilly and Company by 16.8% during the fourth quarter. Private Portfolio Partners LLC now owns 3,189 shares of the company’s stock worth $2,462,000 after acquiring an additional 459 shares during the last quarter. Kesler Norman & Wride LLC raised its position in Eli Lilly and Company by 18.9% during the fourth quarter. Kesler Norman & Wride LLC now owns 4,774 shares of the company’s stock valued at $3,685,000 after purchasing an additional 760 shares during the period. Finally, RFG Bristol Wealth Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $2,071,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Truist Financial boosted their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Citigroup cut their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Bank of America reaffirmed a “buy” rating and set a $997.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a report on Friday, January 17th. Finally, StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,009.72.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $819.57 on Thursday. The firm has a 50 day moving average of $848.85 and a 200 day moving average of $834.05. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The company has a market capitalization of $777.09 billion, a price-to-earnings ratio of 69.99, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a 52 week low of $711.40 and a 52 week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its Board of Directors has authorized a stock repurchase program on Monday, December 9th that allows the company to repurchase $15.00 billion in shares. This repurchase authorization allows the company to reacquire up to 2% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s board believes its shares are undervalued.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.